Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

October 13, 2015November 6, 2015

Aradigm Announces Completion of Patient Enrollment for Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis

Bronchiectasis, News

Aradigm Corporation, a pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases, recently announced the conclusion of patient enrollment in the ... Read more

October 12, 2015November 6, 2015

Study Finds That Daily Exercise Relieves Asthma Symptoms

Asthma, News

Physical activity has been shown to offer various health benefits for patients with asthma, especially in children. However, there is still limited data on the nature of the association between physical activity and ... Read more

October 8, 2015November 5, 2015

Nivalis Announces Positive Data of Phase 1b Study of Experimental Therapy N91115 in Cystic Fibrosis

Cystic Fibrosis, News

Nivalis Therapeutics, Inc., a pharmaceutical company focused on developing treatments for patients with cystic fibrosis (CF), recently announced positive topline data from its Phase 1b trial assessing N91115, an investigational ... Read more

October 7, 2015October 7, 2015

IQWiG Dossier Assessment Shows No Added Benefit of Ceritinib (Zykadia) in NSCLC

Lung Cancer, News

A new report from one of Germany’s public health agencies is shedding new light on an approved therapy often used in the treatment of non-small cell lung cancer. Ceritinib (Zykadia) was approved ... Read more

October 6, 2015November 5, 2015

Raptor Pharmaceutical Acquires Rights To Long-Term Treatment Quinsair For Lung Infections Common in CF Patients

Cystic Fibrosis, News

Raptor Pharmaceutical Corp., a global biopharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases, recently announced that it has acquired the ... Read more

October 5, 2015October 5, 2015

Merck’s Keytruda Receives FDA Approval for Treatment of Advanced Non-small Cell Lung Cancer

Lung Cancer, News

The US FDA recently granted accelerated approval to Merck’s Keytruda (pembrolizumab) as a treatment for advanced (metastatic) non-small cell lung cancer (NSCLC) in patients with disease progression after other therapies have already ... Read more

October 5, 2015November 5, 2015

FDA Approves Combination Therapy of Gilead’s Letairis® Plus Eli Lilly’s Adcirca for patients with Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

Gilead Sciences, recently announced that the FDA has approved of the use of Letairis® (ambrisentan) combined with tadalafil (marketed for PAH under the brand name Adcirca by Eli Lilly) to treat patients with ... Read more

September 30, 2015November 6, 2015

GSK Announces Positive CHMP Opinion in Europe for Severe Refractory Eosinophilic Asthma Drug Mepolizumab

Asthma, News

GlaxoSmithKline, a leading research-based pharmaceutical and healthcare company, recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization ... Read more

September 23, 2015November 5, 2015

Concert Pharma Reports Phase 1 Results of Experimental CF Therapy CTP-656

Cystic Fibrosis, News

Concert Pharma, a biotechnology company utilizing deuterium chemistry to discover and develop innovative drug products that can address unmet medical needs, recently announced positive results from its Phase 1 single ascending dose study ... Read more

September 21, 2015November 6, 2015

Study Determines Individuals with Asthma at Increased Risk for Parkinson’s Disease Later in Life

Asthma, News

Findings from a recent study published in the journal Allergy revealed that individuals with asthma demonstrated an increased risk for Parkinson’s disease later in life. Parkinson’s disease is the second ... Read more